{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T19:24:44Z","timestamp":1794252284541,"version":"4.9.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.lungcan.2026.109465","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T23:23:28Z","timestamp":1779319408000},"page":"109465","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Comparative efficacy of tarlatamab and second-line therapies in extensive-stage small cell lung cancer: A network meta-analysis"],"prefix":"10.1016","volume":"217","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8588-5372","authenticated-orcid":false,"given":"Jessie","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rumbidzai","family":"Takundwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinglei","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youfei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6719-9048","authenticated-orcid":false,"given":"Yuehan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Dirnberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik S.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malaika","family":"Pastel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3324-7398","authenticated-orcid":false,"given":"Xerxes","family":"Pundole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5364-2491","authenticated-orcid":false,"given":"Igor","family":"Gomez-Randulfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Blackhall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.lungcan.2026.109465_b0005","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12890-025-03625-w","article-title":"Factors affecting survival and prognosis in extensive stage small cell lung cancer","volume":"25","author":"Erciyestepe","year":"2025","journal-title":"BMC Pulm. Med."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109465_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.cllc.2024.04.002","article-title":"Small cell lung cancer in Norway: patterns of care by health region and survival trends","volume":"25","author":"Nilssen","year":"2024","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109465_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.112985","article-title":"Trends in theepidemiology of small-cell lung cancer: a Dutch nationwide population-based study over 1989-2020","volume":"191","author":"Dumoulin","year":"2023","journal-title":"Eur. J. Cancer"},{"issue":"23","key":"10.1016\/j.lungcan.2026.109465_b0020","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"10212","key":"10.1016\/j.lungcan.2026.109465_b0025","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.lungcan.2026.109465_b0030","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15164016","article-title":"Small cell lung cancer: Emerging targets and strategies for precision therapy","volume":"15","author":"Patel","year":"2023","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.lungcan.2026.109465_b0035","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK-25-472794","article-title":"Taking a bite out of small cell lung cancer by leveraging precision-directed delta-like ligand-3 therapies","volume":"45","author":"Aijaz","year":"2025","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"5","key":"10.1016\/j.lungcan.2026.109465_b0040","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1470-2045(20)30068-1","article-title":"Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial","volume":"21","author":"Trigo","year":"2020","journal-title":"Lancet Oncol."},{"issue":"35","key":"10.1016\/j.lungcan.2026.109465_b0045","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1200\/JCO.2013.54.5392","article-title":"Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer","volume":"32","author":"von Pawel","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109465_b0050","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2217\/fon-2018-0597","article-title":"ATLANTIS: a phase III study of lurbinectedin\/doxorubicin versus topotecan or cyclophosphamide\/doxorubicin\/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line","volume":"15","author":"Farago","year":"2019","journal-title":"Future Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2026.109465_b0055","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(20)30461-7","article-title":"Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial","volume":"21","author":"Baize","year":"2020","journal-title":"Lancet Oncol."},{"issue":"16","key":"10.1016\/j.lungcan.2026.109465_b0060","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1200\/JCO.22.02823","article-title":"Tarlatamab, a first-in-class DLL3-targeted Bispecific T-Cell engager, in recurrent small-cell lung cancer: an open-label, Phase I study","volume":"41","author":"Paz-Ares","year":"2023","journal-title":"J Clin Oncol."},{"issue":"22","key":"10.1016\/j.lungcan.2026.109465_b0065","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for patients with previously treated small-cell lung cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.lungcan.2026.109465_b0070","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.jtho.2024.09.057","article-title":"OA10. 03. Tarlatamab sustained clinical benefit and safety in previously treated SCLC: DeLLphi-301 phase 2 extended follow-up","volume":"19","author":"Sands","year":"2024","journal-title":"J Thoracic Oncol."},{"key":"10.1016\/j.lungcan.2026.109465_b0075","unstructured":"US Food and Drug Administration. FDA grants accelerated approval to tarlatamab-dlle for extensive stage small cell lung cancer. Accessed August 20, 2025. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-tarlatamab-dlle-extensive-stage-small-cell-lung-cancer."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109465_b0080","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1056\/NEJMoa2502099","article-title":"Tarlatamab in small-cell lung cancer after platinum-based chemotherapy","volume":"393","author":"Mountzios","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109465_b0085","unstructured":"US Food and Drug Administration. FDA grants traditional approval to tarlatamab-dlle for extensive stage small cell lung cancer. 2025. Accessed December 12, 2025. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-traditional-approval-tarlatamab-dlle-extensive-stage-small-cell-lung-cancer."},{"key":"10.1016\/j.lungcan.2026.109465_b0090","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Small Cell Lung Cancer. Version 3.2026. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Guideline Name V.X.20XX. \u00a9 National Comprehensive Cancer Network, Inc. 2026. All rights reserved. To view the most recent and complete version of the guideline, go online to NCCN.org. Accessed August 20, 2025."},{"issue":"7","key":"10.1016\/j.lungcan.2026.109465_b0095","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","article-title":"Small-cell lung cancer: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dingemans","year":"2022","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2026.109465_b0100","doi-asserted-by":"crossref","first-page":"6289","DOI":"10.3390\/curroncol30070465","article-title":"Canadian consensus recommendations on the management of extensive-stage small-cell lung cancer","volume":"30","author":"Melosky","year":"2023","journal-title":"Curr. Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2026.109465_b0105","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1093\/oncolo\/oyae234","article-title":"Recent treatment patterns and real-world survival following first-line anti-PD-L1 treatment for extensive-stage small cell lung cancer","volume":"29","author":"Shaw","year":"2024","journal-title":"Oncologist"},{"issue":"19","key":"10.1016\/j.lungcan.2026.109465_b0110","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1200\/JCO.23.02110","article-title":"RESILIENT Part 2: a randomized, open-label phase iii study of liposomal irinotecan versus topotecan in adults with relapsed small cell lung cancer","volume":"42","author":"Spigel","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109465_b0115","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1200\/JCO.1999.17.2.658","article-title":"Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer","volume":"17","author":"von Pawel","year":"1999","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109465_b0120","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.lungcan.2015.04.012","article-title":"Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 0702","volume":"89","author":"Inoue","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109465_b0125","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.lungcan.2022.03.003","article-title":"Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer","volume":"166","author":"Edelman","year":"2022","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.lungcan.2026.109465_b0130","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1200\/JCO.2010.29.8851","article-title":"Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy","volume":"29","author":"Jotte","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109465_b0135","doi-asserted-by":"crossref","DOI":"10.57264\/cer-2022-0098","article-title":"Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer","volume":"12","author":"Hanvesakul","year":"2023","journal-title":"J. Comp. Eff. Res."},{"key":"10.1016\/j.lungcan.2026.109465_b0140","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1154685","article-title":"Comparison of the second-line treatments for patients with small cell lung cancer sensitive to previous platinum-based chemotherapy: a systematic review and Bayesian network analysis","volume":"13","author":"Shi","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lungcan.2026.109465_b0145","unstructured":"US Food and Drug Administration. FDA approves ovarian cancer Drug. 1996. Accessed September 25, 2025. https:\/\/web.archive.org\/web\/20090119141150\/https:\/\/www.fda.gov\/bbs\/topics\/NEWS\/NEW00537.html."},{"key":"10.1016\/j.lungcan.2026.109465_b0150","unstructured":"European Commission: Member State Coordination Group on Health Technology Assessment. Practical guideline for quantitative evidence synthesis: Direct and indirect comparisons. 2024. Accessed January 14, 2026. https:\/\/health.ec.europa.eu\/document\/download\/1f6b8a70-5ce0-404e-9066-120dc9a8df75_en?filename=hta_practical-guideline_direct-and-indirect-comparisons_en.pdf."},{"key":"10.1016\/j.lungcan.2026.109465_b0155","unstructured":"Dias S, Welton NJ, Sutton AJ, Ades A. NICE DSU technical support document 2: A generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. 2014. Accessed January 14, 2026. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK310366\/."},{"key":"10.1016\/j.lungcan.2026.109465_b0160","unstructured":"European Commission: Member State Coordination Group on Health Technology Assessment. Methodological guideline for quantitative evidence synthesis: Direct and indirect comparisons. Accessed January 14, 2026. https:\/\/health.ec.europa.eu\/latest-updates\/methodological-guideline-quantitative-evidence-synthesis-direct-and-indirect-comparisons-2024-03-25_en."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950022600526X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950022600526X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T01:14:51Z","timestamp":1781140491000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016950022600526X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":32,"alternative-id":["S016950022600526X"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109465","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative efficacy of tarlatamab and second-line therapies in extensive-stage small cell lung cancer: A network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109465","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109465"}}